Conditions in the tender convened for that purpose

They start to be vaccinated girls aged 14 against papillomaviruses
Prevents against cervical cancer, but does not prevent in the future the use of other measures

such as condoms and Pap smears elieves View comments

INFECTION AND CANCER
Infection: Between and percent of women may be affected by the papilloma virus, but only

just in tumor betwee Cancer of the cervix: In Cantabria are recorded between 19 and 40 cases annually, according to

statistics of recent years, which gives an annual average of about 28.

Detection: the extent to locate this tumor is control by gynecologic cytology.

Healing: when the cancer is detected early through the test cytology healing reaches one hundred

percent.

Mortality: women who die from cancer are between age of 8.early olds will start to be vaccinated starting this;

human papilloma virus, specifically against serotypes and which are the main causes of

cervical cancer, a disease with low prevalence in Spain, but it has decided to fight at the state

level. Cantabria will be the fifth autonomy to implement.

Adolescent girls should go to health centres and call your appointment. This is a first dose, a

second and a third a month to six months. In many cases, girls start to be vaccinated with 14

years and finish with . In Cantabria it has been decided to use the age-have reached the age of

14 this year - and not the year of birth so that the coverage was more comprehensive.

Moreover, girls older than this age may choose to be vaccinated buying their dosage, but should

know that protection is not effective if you have already begun sexual intercourse. Otherwise,

there are recommendations that extend up to years, the possibility of being vaccinated.

"The decision to include this vaccine in the schedule was taken unanimously at the technical

presentation in which participated representatives of all the autonomies," explains Alvaro

Gonzalez Aledo, head of the Promotion and Health Education of the Ministry of Health. He added

that in this paper will explore potential vaccines until it decides the "right time" to be

implemented. "Papilloma took time to study and be approved when technicians believe that the

timing," he notes.

Gonzalez Aledo stresses that "prudence" presides over the decisions of the technical

presentation. "In the case of this vaccine, in addition, has heard the voice of the other experts

have advised."

"It should make it clear that the vaccine not only protects against two serotypes of the virus,

although they are the main causes of cervical cancer," said Santiago Rodriguez, director general

of Public Health. In this sense, announced that it will put in place a surveillance system in

collaboration with Pathology de Valdecilla to verify that these are families of the virus which

remain the most common in the future. Such surveillance is conducted through cytology tests.

On the other hand, the manager of Public Health finds that the vaccine is in addition to

preventive measures to care for the health of women. "We are also considering a protocol for the

successful completion of tests on cytology because some women are too often carried out and

others are not accessing them", he stressed.

With regard to cervical cancer, Rodriguez suggests that Spain does not have the same prevalence

among women than in the rest of Europe, where it occupies the top. In our country ranks seventh

after the breast, colon and rectum, stomach, ovarian, lung and pancreas.

Preparations

When the vaccine went on the market six years ago, only one pharmaceutical company offered

preparation (Gardasil). At present, a second has launched its preparation (Cervarix). Cantabria,

which has been the fifth autonomy in launching the vaccination-after Basque Country, Navarra,

Rioja and the Canaries, and has opted for the second offer as it has been proposed that better

conditions in the tender convened for that purpose both price and presentation...